The primary objective of this study is to determine if tumors in patients with papillomavirus
(HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard
therapy will decrease in size following treatment with the investigational drug, rigosertib
sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib
causes any side effects.
Rigosertib is an investigational drug, which means that it has not been approved by the U.S.
Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new
anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by
blocking cell division in cancer cells and causing them to die.